<DOC>
	<DOCNO>NCT00328172</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability several dos BI 1356 BS ( 0.5 , 2.5 5 mg daily ) compare placebo 12 week treatment patient Type 2 diabetes insufficient glycemic control . In addition , open-label treatment arm metformin sensitivity measurement patient population . Population pharmacokinetics BI 1356 BS also assess study .</brief_summary>
	<brief_title>Efficacy Safety 3 Doses BI1356 ( Linagliptin ) Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient diagnosis Type 2 diabetes treat diet exercise ( drug naïve ) one two oral hypoglycemic agent ( single treatment combination ) rosiglitazone pioglitazone treatment . Antidiabetic therapy stable least 10 week prior screen . 2 . Diagnosis Type 2 diabetes duration least 3 month 3 . Glycosylated haemoglobin A1 ( HbA1c ) : 7.510.0 % screen drug naïve patient ( washout need ) 7.09.0 % screen patient treat one oral antidiabetic agent ( washout require ) 6.58.0 % screen patient treat two oral antidiabetic agent ( washout require ) 4 . HbA1c 7.5 % 10.0 % Visit 3 ( begin 2week placebo runin period ) . 5 . Age &gt; =21 &lt; =75 year . 6 . BMI ( Body Mass Index ) &gt; =25.0 &lt; =40 kg/m2 . 7 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Clinically relevant cardiovascular disease ( e.g. , myocardial infarction , stroke transient ischemic attack within six month enrollment ) 2 . Impaired hepatic function define serum level either alanine aminotransferase , aspartate aminotransferase alkaline phosphatase 3fold upper limit normal 3 . Renal insufficiency impair renal function define serum creatinine upper limit normal screen 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder clinically relevant neurologic disorder ( include cerebrovascular exception polyneuropathy ) would interfere participation trial 5 . Chronic clinically relevant acute infection ( e.g. , Human immunodeficiency virus , Hepatitis ) 6 . History relevant allergy/hypersensitivity would interfere trial participation ( include allergy investigational product excipients ) 7 . Treatment rosiglitazone pioglitazone within 6 month prior screen 8 . Treatment insulin within 3 month prior screen 9 . Alcohol drug abuse within last 3 month would interfere trial participation ) 10 . Participation another trial investigational drug within two month prior administration trial 11 . Fasting plasma glucose &gt; 240 mg/dl ( = 13.3 mmol/L ) Visit 2 , 3 4 visit confirm second measurement ( day ) 12 . Premenopausal woman ( last menstruation &lt; =1 year prior sign informed consent ) : 1. surgically sterile , 2. nursing pregnant ; 3. childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include transdermal patch , intrauterine device , oral , implantable injectable contraceptive vasectomise partner . No exception make . 13 . Intolerance metformin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>